| Molecular basis for drug resistance in HIV-1 protease A Ali, RM Bandaranayake, Y Cai, NM King, M Kolli, S Mittal, JF Murzycki, ... Viruses 2 (11), 2509-2535, 2010 | 172 | 2010 |
| Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance M Kolli, E Stawiski, C Chappey, CA Schiffer Journal of virology 83 (21), 11027-11042, 2009 | 71 | 2009 |
| Co-evolution of nelfinavir-resistant HIV-1 protease and the p1–p6 substrate M Kolli, S Lastere, CA Schiffer Virology 347 (2), 405-409, 2006 | 71 | 2006 |
| Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease SK Lee, M Potempa, M Kolli, A Özen, CA Schiffer, R Swanstrom Journal of Biological Chemistry 287 (16), 13279-13290, 2012 | 61 | 2012 |
| The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways RM Bandaranayake, M Kolli, NM King, EA Nalivaika, A Heroux, ... Journal of virology 84 (19), 9995-10003, 2010 | 49 | 2010 |
| Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity CM Parry, M Kolli, RE Myers, PA Cane, C Schiffer, D Pillay Antimicrobial agents and chemotherapy 55 (3), 1106-1113, 2011 | 48 | 2011 |
| HIV-1 protease-substrate coevolution in nelfinavir resistance M Kolli, A Özen, N Kurt-Yilmaz, CA Schiffer Journal of virology 88 (13), 7145-7154, 2014 | 27 | 2014 |
| Insights into the mechanism of resistance-coevolution of the nelfinavir-resistant HIV-1 Protease and the p1-p6 cleavage site M Kolli, CA Schiffer ANTIVIRAL THERAPY 14 (4), A115-A115, 2009 | 1 | 2009 |
| Structural explanations to altered drug resistance pathways in HIV-1 non-clade B proteases RM Bandaranayak, C Ng, M Kolli, M Prabu-Jeyabalan, M Nalam, ... ANTIVIRAL THERAPY 13 (4), A42-A42, 2008 | 1 | 2008 |
| Structural and functional insights into the nelfinavir-resistant HIV-1 protease M Kolli, M Somasundaran, M Prabu-Jeyabalan, S Lastere, CA Schiffer ANTIVIRAL THERAPY 10 (4), S109-S109, 2005 | 1 | 2005 |
| Molecular Basis for Drug Resistance in HIV-1 Protease CA Schiffer, K Thayer, EA Nalivaika, A Özen, MM Prabu-Jeyabalan, ... | | 2010 |
| Interdependency of interactions between D30N/N88D HIV-1 protease and the p1-p6 substrate M Kolli, CA Schiffer ANTIVIRAL THERAPY 15 (4), A85-A85, 2010 | | 2010 |
| Co-evolution of HIV-1 Protease and its Substrates: A Dissertation M Kolli | | 2009 |
| Structural Explanations to Altered Drug Resistance Pathways in HIV-1 Non-Clade B Proteases RM Bandaranayake, M Kolli, M Prabu-Jeyabalan, M Nalam, C Ng, ... Biophysical Journal 96 (3), 447a, 2009 | | 2009 |
| Structural and biochemical insights into altered drug resistance pathways in non-clade B HIV-1 proteases RM Bandaranayake, E Nalivaika, M Kolli, J Kakizawa, A Heroux, NM King, ... ANTIVIRAL THERAPY 14 (4), A111-A111, 2009 | | 2009 |
| Co-evolved protease substrate cleavage site mutations enhance protease inhibitor phenotypic resistance M Kolli, EW Stawiski, C Chappey, NT Parkin, CA Schiffer ANTIVIRAL THERAPY 13 (4), A49-A49, 2008 | | 2008 |
| Signature substrate mutations associated with HIV-1 protease inhibitor resistance M Kolli, E Stawiski, C Chappey, N Parkin, CA Schiffer ANTIVIRAL THERAPY 12, S144-S144, 2007 | | 2007 |
| Identification of novel sites of substrate co-evolution with resistant variants of HIV-1 protease M Kolli, C Chappey, N Parkin, CA Schiffer ANTIVIRAL THERAPY 11 (5), S150-S150, 2006 | | 2006 |
